4.99
+8.01%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shattuck Labs
From its filings with the US Securities and Exchange Commission
Shattuck Labs is based in Austin, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker STTK. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.0m and a net loss of $48.8m. At that date it held total assets of $91.0m and shareholders' equity of $82.4m.
We are a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific Death Receptor 3 (“DR3”) blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Our expertise in protein engineering and the development of novel tumor necrosis factor (“TNF”) receptor therapeutics come together in our lead program, SL-325, a potentially first-in-class DR3 blocking antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway than TL1A blocking antibodies.
SL-325 is a high-affinity DR3 blocking monoclonal antibody. DR3 is the sole known receptor for tumor necrosis factor like ligand 1A (“TL1A”). In our head-to-head preclinical studies, SL-325 blocked TL1A binding to DR3 better than sequence equivalents of leading TL1A blocking antibodies. We believe that the underlying biological differences in the expression of DR3 and TL1A, and the design characteristics of SL-325, may allow SL-325 to achieve best-in-class clinical remission rates in patients with IBD due to a more complete and durable blockade of the clinically validated DR3/TL1A pathway. Additionally, we expect that SL-325 has the potential to demonstrate a superior immunogenicity profile in comparison to TL1A blocking antibodies.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Oct 2020
- Employees
- 40
- Website
- shattucklabs.com ↗
- Head office
- 500 W. 5TH STREET, AUSTIN, TX, 78701
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. George GolumbeskiIndependent Chairman of the Board$171,053
- Dr. Taylor SchreiberChief Executive Officer, Co-Founder, Director, since 2017$3.2m
- Mr. Andrew NeillChief Financial Officer$2.1m
- Dr. Stephen StoutGeneral Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
- Ms. Casi DeyoungChief Business Officer$523,482
- Dr. Arundathy PanditeChief Medical Officer$1.8m
- Dr. Abhinav ShuklaChief Technical Officer$1.2m
- Dr. Mona AshiyaDirector
- Dr. Daniel BakerIndependent Director
- Ms. Helen BoudreauIndependent Director$151,959
- Dr. Neil GibsonIndependent Director$150,234
- Dr. Clay SiegallIndependent Director$380,361
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 22
- Environment
- 21
- Social
- 25
- Governance
- 21
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shattuck Labs focuses on dual-sided fusion proteins for cancer and autoimmune disease treatments.
- SL-172154 is in Phase I trials for ovarian cancer and hematologic malignancies.
- The GADLEN platform targets gamma delta T cells for cancer therapy.
Weaknesses
- Shattuck Labs has only 40 employees, which may limit R&D capacity.
- The company's IPO was in 2020, indicating limited market history.
- SL-172154 is still in Phase I clinical trials, not yet approved.
Opportunities
- Shattuck Labs' SL-172154 could expand to treat additional cancers in future trials.
- The GADLEN platform offers potential for new cancer therapies beyond current applications.
- Ovarian cancer and AML markets present significant growth opportunities.
Threats
- Phase I trials for SL-172154 may fail, delaying product approval.
- Competition in biotechnology could emerge from larger firms with more resources.
- Regulatory hurdles might slow down clinical trial progress for new therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.